Viatris (VTRS) Cash from Financing Activities (2019 - 2026)
Viatris' (VTRS) quarterly Cash from Financing Activities came in at -$203.8 million in Q1 2026, up 56.36% year-on-year from -$130.3 million in Q1 2025, and up 13.79% quarter-over-quarter from -$236.4 million in Q4 2025.
Viatris (VTRS) Cash from Financing Activities (2019 - 2026) Analysis & Trends
Viatris' Cash from Financing Activities history runs 8 years deep, the most recent figure standing at -$203.8 million for Q1 2026.
- On a quarterly basis, Cash from Financing Activities rose 56.36% year-over-year to -$203.8 million in Q1 2026; TTM through Mar 2026 was -$1.0 billion, a 76.42% increase from a year earlier, with the FY2025 full-year figure at -$1.3 billion, up 70.12% from the prior year.
- Cash from Financing Activities climbed to -$203.8 million in Q1 2026 per VTRS's latest filing, from -$236.4 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at -$97.6 million in Q3 2023 and bottomed at -$1.6 billion in Q3 2024.
- The 5-year median for Cash from Financing Activities is -$758.7 million (2022), against an average of -$706.3 million.
- Across the five-year window, Cash from Financing Activities jumped 87.14% in 2023 and plunged 1576.95% in 2024, its largest moves.
- Year by year, Cash from Financing Activities stood at -$1.3 billion in 2022, then surged by 30.4% to -$926.1 million in 2023, then slumped by 53.35% to -$1.4 billion in 2024, then surged by 83.35% to -$236.4 million in 2025, then increased by 13.79% to -$203.8 million in 2026.
- Per Business Quant, the three latest VTRS Cash from Financing Activities figures stand at -$203.8 million (Q1 2026), -$236.4 million (Q4 2025), and -$228.1 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 13.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -840.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -494.13 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -1.48 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -203.80 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -86.10 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -65.00 Mn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | -4.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -203.80 Mn |
| Mar 31, 2026 | -203.80 Mn |
| Dec 31, 2025 | -236.40 Mn |
| Dec 31, 2025 | -236.40 Mn |
| Sep 30, 2025 | -228.10 Mn |
| Sep 30, 2025 | -228.10 Mn |
| Jun 30, 2025 | -362.40 Mn |
| Jun 30, 2025 | -362.40 Mn |
| Mar 31, 2025 | -467.00 Mn |
| Mar 31, 2025 | -467.00 Mn |
| Dec 31, 2024 | -1.42 Bn |
| Dec 31, 2024 | -1.42 Bn |
| Sep 30, 2024 | -1.64 Bn |
| Sep 30, 2024 | -1.64 Bn |
| Jun 30, 2024 | -847.90 Mn |
| Jun 30, 2024 | -847.90 Mn |
| Mar 31, 2024 | -425.60 Mn |
| Mar 31, 2024 | -425.60 Mn |
| Dec 31, 2023 | -926.10 Mn |
| Dec 31, 2023 | -926.10 Mn |